PortalPublikationenTERT Promoter Mutations and Risk of Recurrence in Meningioma

TERT Promoter Mutations and Risk of Recurrence in Meningioma

Standard

TERT Promoter Mutations and Risk of Recurrence in Meningioma. / Sahm, Felix; Schrimpf, Daniel; Olar, Adriana; Koelsche, Christian; Reuss, David; Bissel, Juliane; Kratz, Annekathrin; Capper, David; Schefzyk, Sebastian; Hielscher, Thomas; Wang, Qianghu; Sulman, Erik P; Adeberg, Sebastian; Koch, Arend; Okuducu, Ali Fuat; Brehmer, Stefanie; Schittenhelm, Jens; Becker, Albert; Brokinkel, Benjamin; Schmidt, Melissa; Ull, Theresa; Gousias, Konstantinos; Kessler, Almuth Friederike; Lamszus, Katrin; Debus, Jürgen; Mawrin, Christian; Kim, Yoo-Jin; Simon, Matthias; Ketter, Ralf; Paulus, Werner; Aldape, Kenneth D; Herold-Mende, Christel; von Deimling, Andreas.

in: JNCI-J NATL CANCER I, Jahrgang 108, Nr. 5, 05.2016.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sahm, F, Schrimpf, D, Olar, A, Koelsche, C, Reuss, D, Bissel, J, Kratz, A, Capper, D, Schefzyk, S, Hielscher, T, Wang, Q, Sulman, EP, Adeberg, S, Koch, A, Okuducu, AF, Brehmer, S, Schittenhelm, J, Becker, A, Brokinkel, B, Schmidt, M, Ull, T, Gousias, K, Kessler, AF, Lamszus, K, Debus, J, Mawrin, C, Kim, Y-J, Simon, M, Ketter, R, Paulus, W, Aldape, KD, Herold-Mende, C & von Deimling, A 2016, 'TERT Promoter Mutations and Risk of Recurrence in Meningioma', JNCI-J NATL CANCER I, Jg. 108, Nr. 5. https://doi.org/10.1093/jnci/djv377

APA

Sahm, F., Schrimpf, D., Olar, A., Koelsche, C., Reuss, D., Bissel, J., Kratz, A., Capper, D., Schefzyk, S., Hielscher, T., Wang, Q., Sulman, E. P., Adeberg, S., Koch, A., Okuducu, A. F., Brehmer, S., Schittenhelm, J., Becker, A., Brokinkel, B., ... von Deimling, A. (2016). TERT Promoter Mutations and Risk of Recurrence in Meningioma. JNCI-J NATL CANCER I, 108(5). https://doi.org/10.1093/jnci/djv377

Vancouver

Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J et al. TERT Promoter Mutations and Risk of Recurrence in Meningioma. JNCI-J NATL CANCER I. 2016 Mai;108(5). https://doi.org/10.1093/jnci/djv377

Bibtex

@article{fd73a163b3f74bbc8d14321543e307cd,
title = "TERT Promoter Mutations and Risk of Recurrence in Meningioma",
abstract = "The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.",
keywords = "Adult, Aged, Biomarkers, Tumor, Disease Progression, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Male, Meningeal Neoplasms, Meningioma, Middle Aged, Mutation, Neoplasm Grading, Neoplasm Recurrence, Local, Predictive Value of Tests, Prognosis, Promoter Regions, Genetic, Proportional Hazards Models, Telomerase, Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't",
author = "Felix Sahm and Daniel Schrimpf and Adriana Olar and Christian Koelsche and David Reuss and Juliane Bissel and Annekathrin Kratz and David Capper and Sebastian Schefzyk and Thomas Hielscher and Qianghu Wang and Sulman, {Erik P} and Sebastian Adeberg and Arend Koch and Okuducu, {Ali Fuat} and Stefanie Brehmer and Jens Schittenhelm and Albert Becker and Benjamin Brokinkel and Melissa Schmidt and Theresa Ull and Konstantinos Gousias and Kessler, {Almuth Friederike} and Katrin Lamszus and J{\"u}rgen Debus and Christian Mawrin and Yoo-Jin Kim and Matthias Simon and Ralf Ketter and Werner Paulus and Aldape, {Kenneth D} and Christel Herold-Mende and {von Deimling}, Andreas",
note = "{\textcopyright} The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.",
year = "2016",
month = may,
doi = "10.1093/jnci/djv377",
language = "English",
volume = "108",
journal = "JNCI-J NATL CANCER I",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - TERT Promoter Mutations and Risk of Recurrence in Meningioma

AU - Sahm, Felix

AU - Schrimpf, Daniel

AU - Olar, Adriana

AU - Koelsche, Christian

AU - Reuss, David

AU - Bissel, Juliane

AU - Kratz, Annekathrin

AU - Capper, David

AU - Schefzyk, Sebastian

AU - Hielscher, Thomas

AU - Wang, Qianghu

AU - Sulman, Erik P

AU - Adeberg, Sebastian

AU - Koch, Arend

AU - Okuducu, Ali Fuat

AU - Brehmer, Stefanie

AU - Schittenhelm, Jens

AU - Becker, Albert

AU - Brokinkel, Benjamin

AU - Schmidt, Melissa

AU - Ull, Theresa

AU - Gousias, Konstantinos

AU - Kessler, Almuth Friederike

AU - Lamszus, Katrin

AU - Debus, Jürgen

AU - Mawrin, Christian

AU - Kim, Yoo-Jin

AU - Simon, Matthias

AU - Ketter, Ralf

AU - Paulus, Werner

AU - Aldape, Kenneth D

AU - Herold-Mende, Christel

AU - von Deimling, Andreas

N1 - © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PY - 2016/5

Y1 - 2016/5

N2 - The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.

AB - The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.

KW - Adult

KW - Aged

KW - Biomarkers, Tumor

KW - Disease Progression

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Meningeal Neoplasms

KW - Meningioma

KW - Middle Aged

KW - Mutation

KW - Neoplasm Grading

KW - Neoplasm Recurrence, Local

KW - Predictive Value of Tests

KW - Prognosis

KW - Promoter Regions, Genetic

KW - Proportional Hazards Models

KW - Telomerase

KW - Comparative Study

KW - Journal Article

KW - Research Support, N.I.H., Extramural

KW - Research Support, Non-U.S. Gov't

U2 - 10.1093/jnci/djv377

DO - 10.1093/jnci/djv377

M3 - SCORING: Journal article

C2 - 26668184

VL - 108

JO - JNCI-J NATL CANCER I

JF - JNCI-J NATL CANCER I

SN - 0027-8874

IS - 5

ER -